LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Minerva Neurosciences Inc

Chiusa

1.57 -1.26

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.55

Massimo

1.6

Metriche Chiave

By Trading Economics

P/E

Media del settore

8.294

54.379

Dipendenti

8

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+210.56% upside

Dividendi

By Dow Jones

Utili prossimi

14 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2.2M

11M

Apertura precedente

2.83

Chiusura precedente

1.57

Minerva Neurosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 mag 2025, 23:59 UTC

Notizie principali
Utili

Naver 1Q Net Slumps on Higher Costs

8 mag 2025, 23:39 UTC

Utili

OCBC 1Q Net Down on Lower Interest Income

8 mag 2025, 23:01 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mag 2025, 22:52 UTC

Utili

REA Expects Annual Listings Growth Despite April Decline

8 mag 2025, 22:46 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mag 2025, 23:41 UTC

Discorsi di Mercato

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mag 2025, 23:30 UTC

Utili

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mag 2025, 23:29 UTC

Utili

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mag 2025, 23:05 UTC

Discorsi di Mercato

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mag 2025, 23:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:01 UTC

Notizie principali

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mag 2025, 22:28 UTC

Utili

REA Expects FY 2025 Listings Growth of 1-2%

8 mag 2025, 22:28 UTC

Utili

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mag 2025, 22:27 UTC

Utili

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mag 2025, 22:27 UTC

Utili

REA Says April Residential Listings Fell by 11% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Confronto tra pari

Modifica del prezzo

Minerva Neurosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

210.56% in crescita

Previsioni per 12 mesi

Media 5 USD  210.56%

Alto 5 USD

Basso 5 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Minerva Neurosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

0

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

$

Chi Siamo Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.